CN104971265A - Medicine composition for treating exudative age-related macular degeneration - Google Patents
Medicine composition for treating exudative age-related macular degeneration Download PDFInfo
- Publication number
- CN104971265A CN104971265A CN201410504848.8A CN201410504848A CN104971265A CN 104971265 A CN104971265 A CN 104971265A CN 201410504848 A CN201410504848 A CN 201410504848A CN 104971265 A CN104971265 A CN 104971265A
- Authority
- CN
- China
- Prior art keywords
- parts
- grams
- radix
- herba
- macular degeneration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine composition for treating exudative age-related macular degeneration, which includes the following components, by weight, 50-200 parts of coix seeds, 50-150 parts of ficus carica, 100-200 parts of ottelia alismoides, 50-150 parts of artemisiae scopariae, 100-200 parts of myrrh, 100-200 parts of hedyotis hedyotidea, 100-200 parts of prepared rehmannia root, 100-200 parts of drymoglossum piloselloides, 50-150 parts of chinese yam, 50-150 parts of semen cuscutae, 50-100 parts of actinidia arguta, 100-200 parts of storax, 50-100 parts of rubia cordifolia, 50-200 parts of maesa japonica, 100-200 parts of white peony roots, 100-200 parts of honeysuckles, 50-100 parts of Chinese prickly ash, 50-100 parts of pulsatilla chinensis, 50-150 parts of sida szechuensis, 50-150 parts of fructus cnidii and 50-100 parts of radix glycyrrhizae. The invention also provides a preparation method of the medicine composition. The components in the medicine composition are interacted on each other and achieve a synergistic effect, so that the medicine composition is significant in an effect of treating the exudative age-related macular degeneration and is valuable to clinically popularize.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to pharmaceutical composition of a kind of nursing for treating exudative age-related macular degeneration and preparation method thereof.
Background technology
Exudative age-related macular degeneration is the one of senile degeneration of macula.The feature of primary disease is have neovascular membranes to exist under retinal pigment epithelium, thus cause a series ofly to ooze out, hemorrhage change, visual deterioration is more anxious.Primary disease betides more than 45 years old mostly, and prevalence increases with the age and increases, and is the first cause of the developed country over-65s old people blindings such as America and Europe, the important diseases of the current old people's blinding of Yi Shi China.
Summary of the invention
The object of this invention is to provide a kind of pharmaceutical composition for the treatment of exudative age-related macular degeneration.
The present invention also aims to the preparation method that this pharmaceutical composition is provided.
In order to realize object of the present invention, the invention provides a kind of pharmaceutical composition for the treatment of exudative age-related macular degeneration, it comprises the material of following weight portion: Semen Coicis 50-200 part, Fructus Fici 50-150 part, Herba Otteliae Alismoidis 100-200 part, Herba Artemisiae Scopariae 50-150 part, Myrrha 100-200 part, Caulis et Folium hedyotis hedyotideae 100-200 part, Radix Rehmanniae Preparata 100-200 part, Drymoglossum Herba Drymoglossi 100-200 part, Rhizoma Dioscoreae 50-150 part, Semen Cuscutae 50-150 part, Fructus Actinidiae Argutae 50-100 part, Styrax 100-200 part, Radix Rubiae 50-100 part, Radix Maesae Japonicae 50-200 part, Radix Paeoniae Alba 100-200 part, Flos Lonicerae 100-200 part, Pericarpium Zanthoxyli 50-100 part, Radix Pulsatillae 50-100 part, Herba Sidae Szechuensis 50-150 part, Fructus Cnidii 50-150 part and Radix Glycyrrhizae 50-100 part.
Preferably, the pharmaceutical composition for the treatment of exudative age-related macular degeneration of the present invention comprises the material of following weight portion: Semen Coicis 100 parts, Fructus Fici 80 parts, Herba Otteliae Alismoidis 120 parts, Herba Artemisiae Scopariae 90 parts, Myrrha 120 parts, Caulis et Folium hedyotis hedyotideae 150 parts, Radix Rehmanniae Preparata 140 parts, Drymoglossum Herba Drymoglossi 120 parts, Rhizoma Dioscoreae 100 parts, Semen Cuscutae 80 parts, Fructus Actinidiae Argutae 60 parts, Styrax 110 parts, 70 parts, Radix Rubiae, Radix Maesae Japonicae 100 parts, the Radix Paeoniae Alba 130 parts, Flos Lonicerae 150 parts, 80 parts, Pericarpium Zanthoxyli, the Radix Pulsatillae 90 parts, Herba Sidae Szechuensis 70 parts, Fructus Cnidii 80 parts and 70 parts, Radix Glycyrrhizae.
Preferably, the pharmaceutical composition for the treatment of exudative age-related macular degeneration of the present invention comprises the material of following weight portion: Semen Coicis 180 parts, Fructus Fici 110 parts, Herba Otteliae Alismoidis 150 parts, Herba Artemisiae Scopariae 130 parts, Myrrha 140 parts, Caulis et Folium hedyotis hedyotideae 170 parts, Radix Rehmanniae Preparata 160 parts, Drymoglossum Herba Drymoglossi 130 parts, Rhizoma Dioscoreae 110 parts, Semen Cuscutae 130 parts, Fructus Actinidiae Argutae 90 parts, Styrax 160 parts, 80 parts, Radix Rubiae, Radix Maesae Japonicae 130 parts, the Radix Paeoniae Alba 140 parts, Flos Lonicerae 180 parts, 90 parts, Pericarpium Zanthoxyli, the Radix Pulsatillae 80 parts, Herba Sidae Szechuensis 140 parts, Fructus Cnidii 130 parts and 90 parts, Radix Glycyrrhizae.
More preferably, described pharmaceutical composition can be tablet, dispersible tablet, capsule, soft capsule or decoction.
The present invention also provides a kind of preparation method for the treatment of the pharmaceutical composition of exudative age-related macular degeneration, and the method comprises the following steps:
1) Styrax 110 grams is taken, add 2000 milliliters, water and extract volatile oil, described volatile oil is added 60 grams of beta-schardinger dextrin-s to stir at 60 DEG C and carry out enclose in 2 hours, to obtain volatile oil clathrate compound, when in addition aqueous extract being concentrated into 50 DEG C, relative density is the clear paste of 1.20;
2) Semen Coicis 100 grams, Fructus Fici 80 grams, Herba Otteliae Alismoidis 120 grams, Herba Artemisiae Scopariae 90 grams, Myrrha 120 grams, Caulis et Folium hedyotis hedyotideae 150 grams, Radix Rehmanniae Preparata 140 grams, Drymoglossum Herba Drymoglossi 120 grams, Rhizoma Dioscoreae 100 grams, Semen Cuscutae 80 grams, Fructus Actinidiae Argutae 60 grams is taken, add 6000 ml waters, heating 3 hours under the condition of backflow, be cooled to room temperature, filter, in filtrate, add ethanol to alcohol content is 75%, kept at room temperature overnight, filter, the ethanol in filtrate is reclaimed to be concentrated into 50 DEG C completely time relative density be the clear paste of 1.20;
3) 70 grams, Radix Rubiae, Radix Maesae Japonicae 100 grams, the Radix Paeoniae Alba 130 grams, Flos Lonicerae 150 grams, 80 grams, Pericarpium Zanthoxyli, the Radix Pulsatillae 90 grams, Herba Sidae Szechuensis 70 grams, Fructus Cnidii 80 grams and 70 grams, Radix Glycyrrhizae is taken, add the ethanol water of 2000 milliliter of 85 volume %, heat 5 hours at 50 DEG C, be cooled to room temperature, filter, the ethanol in filtrate is reclaimed to be concentrated into 50 DEG C completely time relative density be the clear paste of 1.20; And
4) merge described step 1), step 2) and step 3) in clear paste and step 1) in volatile oil clathrate compound, pulverize, mix homogeneously, adds hyprolose 15 grams, lactose 70 grams, starch 15 grams, microcrystalline Cellulose 45 grams, mixing, cross 80 mesh sieves, water spray makes soft material, crosses 60 mesh sieves, dry, add sodium carboxymethyl cellulose 8 grams and magnesium stearate 1.5 grams, mix homogeneously, is pressed into 1000.
Generally acknowledged that " organic conception ", " determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs ", " compound recipe use ", " compound compatibility medication is as used military forces " are the traditional Chinese medical science the most effective most scientific several large advantages at present, wherein " compound compatibility medication is as used military forces " is the original theory of Chinese medicine of very science.The tight compatibility that in traditional Chinese medical science prescription, each medicine is all linked with one another as arrayed troops for battle is that it is better than the effective means of Western medicine formula.Tcm prescription theory is thought, each prescription, not only need to select the appropriate compatibility of suitable pharmaceutical composition according to etiology and pathogenesis, also should meet the basic structure of prescription simultaneously, the i.e. prescription compatibility theory of " monarch, minister, help, make ", the prescription compatibility of so-called " monarch, minister, help, make " is exactly that it is based upon the scientific matching on the comprehensive judgement basis of disease pathogenesis.In medical side by too many levels, Mutiple Targets Integrate adjustment biological mechanism, can to obtain than Western medicine more lastingly, the more therapeutic effect that has no side effect of green natural, and this curative effect be based upon the above-mentioned traditional Chinese medical science tradition original theory accurate instruction on, the present invention just have followed this principle.
In the present compositions, Caulis et Folium hedyotis hedyotideae and Drymoglossum Herba Drymoglossi are monarch drug; Semen Coicis, Fructus Fici, Herba Otteliae Alismoidis, Herba Artemisiae Scopariae, Myrrha, Radix Rehmanniae Preparata, Rhizoma Dioscoreae, Semen Cuscutae, Fructus Actinidiae Argutae, Styrax are ministerial drug; Radix Rubiae, Radix Maesae Japonicae, the Radix Paeoniae Alba, Flos Lonicerae, Pericarpium Zanthoxyli, the Radix Pulsatillae, Herba Sidae Szechuensis, Fructus Cnidii are adjuvant drug; Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, for making medicine.Pharmaceutical composition of the present invention interacts, and synergism complements each other, and plays the merit of monarch altogether, and treatment exudative age-related macular degeneration Be very effective, clinic is promoted.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percent in the present invention is percetage by weight.
Embodiment tablet of the present invention
1) Styrax 110 grams is taken, add 2000 milliliters, water and extract volatile oil, described volatile oil is added 60 grams of beta-schardinger dextrin-s to stir at 60 DEG C and carry out enclose in 2 hours, to obtain volatile oil clathrate compound, when in addition aqueous extract being concentrated into 50 DEG C, relative density is the clear paste of 1.20;
2) Semen Coicis 100 grams, Fructus Fici 80 grams, Herba Otteliae Alismoidis 120 grams, Herba Artemisiae Scopariae 90 grams, Myrrha 120 grams, Caulis et Folium hedyotis hedyotideae 150 grams, Radix Rehmanniae Preparata 140 grams, Drymoglossum Herba Drymoglossi 120 grams, Rhizoma Dioscoreae 100 grams, Semen Cuscutae 80 grams, Fructus Actinidiae Argutae 60 grams is taken, add 6000 ml waters, heating 3 hours under the condition of backflow, be cooled to room temperature, filter, in filtrate, add ethanol to alcohol content is 75%, kept at room temperature overnight, filter, the ethanol in filtrate is reclaimed to be concentrated into 50 DEG C completely time relative density be the clear paste of 1.20;
3) 70 grams, Radix Rubiae, Radix Maesae Japonicae 100 grams, the Radix Paeoniae Alba 130 grams, Flos Lonicerae 150 grams, 80 grams, Pericarpium Zanthoxyli, the Radix Pulsatillae 90 grams, Herba Sidae Szechuensis 70 grams, Fructus Cnidii 80 grams and 70 grams, Radix Glycyrrhizae is taken, add the ethanol water of 2000 milliliter of 85 volume %, heat 5 hours at 50 DEG C, be cooled to room temperature, filter, the ethanol in filtrate is reclaimed to be concentrated into 50 DEG C completely time relative density be the clear paste of 1.20; And
4) merge described step 1), step 2) and step 3) in clear paste and step 1) in volatile oil clathrate compound, pulverize, mix homogeneously, adds hyprolose 15 grams, lactose 70 grams, starch 15 grams, microcrystalline Cellulose 45 grams, mixing, cross 80 mesh sieves, water spray makes soft material, crosses 60 mesh sieves, dry, add sodium carboxymethyl cellulose 8 grams and magnesium stearate 1.5 grams, mix homogeneously, is pressed into 1000.
Experimental example
Diagnostic criteria
" the basic diagnosis and treatment specification of Guangdong Province's commonly encountered diseases " of publishing according to Department of Health of Guangdong Province (Huang Qingdao, Zhong Nanshan's age-related macular degeneration diagnostic criteria [S]. the basic diagnosis and treatment specification 2003.1:119 of Guangdong Province's commonly encountered diseases) age-related macular degeneration diagnostic criteria.
Select the patient 80 meeting above-mentioned diagnostic criteria that in March ,-2014 in February, 20013, my institute tidied up example, wherein man 40 example, female 40 example, age 46-71 year, the mean age (65.9 ± 0.3) year; Suffer from eye, early stage 61, mid-term 62, late period 5, course of disease 0.5-2 for 128.
The tablet prepared in embodiment is used to treat, every day 2 times, oral 1 at every turn, treatment 7 days continuously.
The standard of curative effect evaluation
The age-related macular degeneration criterion of therapeutical effect of " the basic diagnosis and treatment specification of Guangdong Province's commonly encountered diseases " that criterion of therapeutical effect is published with reference to Department of Health of Guangdong Province.Cure: the absorptions such as macular diseases stops progress, hemorrhage, to ooze out, eyesight improving more than 0.2 (logarithmic visual acuity chart improves two row), follow up a case by regular visits to three months without recurrence.Take a turn for the better: macular diseases stops progress or progression, and hemorrhage, ooze out etc. partially absorbs, and eyesight improving is not obvious, follows up a case by regular visits to and has recurrence in three months.Invalid: not reach improvement standard.
Result
Through treatment, cure 52 examples in 80 routine patients, take a turn for the better 27 examples, invalid 1 example, total effective rate 98.75%.
Typical case
Zhang, man, 61 years old, with Binocular vison Before-daybreak half a year, increases the weight of to be chief complaint for 1 month and comes to go to a doctor, and see time medical that patient is conscious dark at the moment, metamorphopsia, crimson tongue tongue is white, stringy pulse.Check: distant vision right eye 4.3, left eye 4.2; Two external eyes no abnormality seen, crystal periphery slight haziness, fundus flavimaculatus portion sees that old oozes out stove, the reflective disappearance of central fovea; Fundus fluorescein angiography is shown in that eyes macular area choroidal neovascularization is formed, and occurs fluorescence leakage, and left eye has one hemorrhagely to block phosphor region.Diagnosis exudative age-related macular degeneration.The tablet prepared in embodiment is used to treat, every day 2 times, oral 1 at every turn, treatment 7 days continuously.Check after one week, patient is conscious, and binocular vision significantly improves, and surveys distant vision right eye 4.7, left eye 4.6, the absorptions such as macular diseases stops progress, hemorrhage, to ooze out.Follow up a case by regular visits to three months binocular visions and keep stable, examination of ocular fundus macular diseases stops progress, hemorrhage, ooze out absorption, without recurrence, and recovery from illness.
Claims (5)
1. treat the pharmaceutical composition of exudative age-related macular degeneration for one kind, it is characterized in that, it comprises the material of following weight portion: Semen Coicis 50-200 part, Fructus Fici 50-150 part, Herba Otteliae Alismoidis 100-200 part, Herba Artemisiae Scopariae 50-150 part, Myrrha 100-200 part, Caulis et Folium hedyotis hedyotideae 100-200 part, Radix Rehmanniae Preparata 100-200 part, Drymoglossum Herba Drymoglossi 100-200 part, Rhizoma Dioscoreae 50-150 part, Semen Cuscutae 50-150 part, Fructus Actinidiae Argutae 50-100 part, Styrax 100-200 part, Radix Rubiae 50-100 part, Radix Maesae Japonicae 50-200 part, Radix Paeoniae Alba 100-200 part, Flos Lonicerae 100-200 part, Pericarpium Zanthoxyli 50-100 part, Radix Pulsatillae 50-100 part, Herba Sidae Szechuensis 50-150 part, Fructus Cnidii 50-150 part and Radix Glycyrrhizae 50-100 part.
2. the pharmaceutical composition for the treatment of exudative age-related macular degeneration according to claim 1, it is characterized in that, it comprises the material of following weight portion: Semen Coicis 100 parts, Fructus Fici 80 parts, Herba Otteliae Alismoidis 120 parts, Herba Artemisiae Scopariae 90 parts, Myrrha 120 parts, Caulis et Folium hedyotis hedyotideae 150 parts, Radix Rehmanniae Preparata 140 parts, Drymoglossum Herba Drymoglossi 120 parts, Rhizoma Dioscoreae 100 parts, Semen Cuscutae 80 parts, Fructus Actinidiae Argutae 60 parts, Styrax 110 parts, 70 parts, Radix Rubiae, Radix Maesae Japonicae 100 parts, the Radix Paeoniae Alba 130 parts, Flos Lonicerae 150 parts, 80 parts, Pericarpium Zanthoxyli, the Radix Pulsatillae 90 parts, Herba Sidae Szechuensis 70 parts, Fructus Cnidii 80 parts and 70 parts, Radix Glycyrrhizae.
3. the pharmaceutical composition for the treatment of exudative age-related macular degeneration according to claim 1, it is characterized in that, it comprises the material of following weight portion: Semen Coicis 180 parts, Fructus Fici 110 parts, Herba Otteliae Alismoidis 150 parts, Herba Artemisiae Scopariae 130 parts, Myrrha 140 parts, Caulis et Folium hedyotis hedyotideae 170 parts, Radix Rehmanniae Preparata 160 parts, Drymoglossum Herba Drymoglossi 130 parts, Rhizoma Dioscoreae 110 parts, Semen Cuscutae 130 parts, Fructus Actinidiae Argutae 90 parts, Styrax 160 parts, 80 parts, Radix Rubiae, Radix Maesae Japonicae 130 parts, the Radix Paeoniae Alba 140 parts, Flos Lonicerae 180 parts, 90 parts, Pericarpium Zanthoxyli, the Radix Pulsatillae 80 parts, Herba Sidae Szechuensis 140 parts, Fructus Cnidii 130 parts and 90 parts, Radix Glycyrrhizae.
4. the pharmaceutical composition of the treatment exudative age-related macular degeneration according to any one of claim 1-3, is characterized in that, described pharmaceutical composition can be tablet, dispersible tablet, capsule, soft capsule or decoction.
5. treat a preparation method for the pharmaceutical composition of exudative age-related macular degeneration, the method comprises the following steps:
1) Styrax 110 grams is taken, add 2000 milliliters, water and extract volatile oil, described volatile oil is added 60 grams of beta-schardinger dextrin-s to stir at 60 DEG C and carry out enclose in 2 hours, to obtain volatile oil clathrate compound, when in addition aqueous extract being concentrated into 50 DEG C, relative density is the clear paste of 1.20;
2) Semen Coicis 100 grams, Fructus Fici 80 grams, Herba Otteliae Alismoidis 120 grams, Herba Artemisiae Scopariae 90 grams, Myrrha 120 grams, Caulis et Folium hedyotis hedyotideae 150 grams, Radix Rehmanniae Preparata 140 grams, Drymoglossum Herba Drymoglossi 120 grams, Rhizoma Dioscoreae 100 grams, Semen Cuscutae 80 grams, Fructus Actinidiae Argutae 60 grams is taken, add 6000 ml waters, heating 3 hours under the condition of backflow, be cooled to room temperature, filter, in filtrate, add ethanol to alcohol content is 75%, kept at room temperature overnight, filter, the ethanol in filtrate is reclaimed to be concentrated into 50 DEG C completely time relative density be the clear paste of 1.20;
3) 70 grams, Radix Rubiae, Radix Maesae Japonicae 100 grams, the Radix Paeoniae Alba 130 grams, Flos Lonicerae 150 grams, 80 grams, Pericarpium Zanthoxyli, the Radix Pulsatillae 90 grams, Herba Sidae Szechuensis 70 grams, Fructus Cnidii 80 grams and 70 grams, Radix Glycyrrhizae is taken, add the ethanol water of 2000 milliliter of 85 volume %, heat 5 hours at 50 DEG C, be cooled to room temperature, filter, the ethanol in filtrate is reclaimed to be concentrated into 50 DEG C completely time relative density be the clear paste of 1.20; And
4) merge described step 1), step 2) and step 3) in clear paste and step 1) in volatile oil clathrate compound, pulverize, mix homogeneously, adds hyprolose 15 grams, lactose 70 grams, starch 15 grams, microcrystalline Cellulose 45 grams, mixing, cross 80 mesh sieves, water spray makes soft material, crosses 60 mesh sieves, dry, add sodium carboxymethyl cellulose 8 grams and magnesium stearate 1.5 grams, mix homogeneously, is pressed into 1000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410504848.8A CN104971265A (en) | 2014-09-27 | 2014-09-27 | Medicine composition for treating exudative age-related macular degeneration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410504848.8A CN104971265A (en) | 2014-09-27 | 2014-09-27 | Medicine composition for treating exudative age-related macular degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104971265A true CN104971265A (en) | 2015-10-14 |
Family
ID=54268585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410504848.8A Pending CN104971265A (en) | 2014-09-27 | 2014-09-27 | Medicine composition for treating exudative age-related macular degeneration |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104971265A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474368A (en) * | 2008-11-28 | 2009-07-08 | 安徽省药物研究所 | Chinese medicine for treating macular degeneration related to age and preparation method |
-
2014
- 2014-09-27 CN CN201410504848.8A patent/CN104971265A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474368A (en) * | 2008-11-28 | 2009-07-08 | 安徽省药物研究所 | Chinese medicine for treating macular degeneration related to age and preparation method |
Non-Patent Citations (2)
| Title |
|---|
| 李学晶等: "年龄相关性黄斑变性的中医认识", 《中国中医眼科杂志》 * |
| 魏树瑾等: "中医治疗渗出型老年性黄斑变性一例", 《天津医药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103169849B (en) | Pharmaceutical composition for treating sore carbuncle swollen poison, and preparation method and use thereof | |
| CN102727858B (en) | Medical composition for treating headaches and migraine, preparation method and application thereof | |
| CN104971265A (en) | Medicine composition for treating exudative age-related macular degeneration | |
| CN102379967A (en) | Traditional Chinese medicine for treating diabetic retinopathy | |
| CN104306546A (en) | A traditional Chinese medicine composition used for treating optic atrophy, and decoctions, pills and powder of the composition | |
| CN104225344A (en) | Chinese herbal preparation for treating chronic nephropyelitis and preparation method thereof | |
| CN103705899A (en) | Pharmaceutical composition for treating diabetic retinopathy and preparation method and use thereof | |
| CN103550744A (en) | Pure traditional Chinese medicine preparation for dental ulcers | |
| CN103520684A (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN101966258A (en) | Traditional Chinese medicine for treating diabetic retinopathy | |
| CN105521026A (en) | Injection for treating epidemic cerebrospinal meningitis | |
| CN104623282A (en) | Traditional Chinese medicine healthy preparation for conditioning hypertension | |
| CN102114121A (en) | Traditional Chinese medicine for treating diabetic retinopathy | |
| CN101979040B (en) | Medicament for treating central serous chorioretinopathy | |
| CN105521431B (en) | A Chinese medicinal composition for treating diabetes and its complications, and its preparation method | |
| CN102973774B (en) | Medicine composition for treating speckles and preparation method and application of composition | |
| CN101972343A (en) | Traditional Chinese medicine for treating diabetic oculopathy | |
| CN101953938A (en) | Traditional Chinese medicine for treating diabetic retinopathy | |
| CN101940659A (en) | Traditional Chinese medicine for treating diabetic eye disease | |
| CN101953939A (en) | Chinese medicament for treating diabetic eye diseases | |
| CN107837370A (en) | It is a kind of treat liver heat caused by blood-shoot-eye illness Chinese medicine composition and its application method | |
| CN101129837A (en) | Proprietary Chinese medicine for treating retina affection of diabetes | |
| CN105381100A (en) | Medicine composition for treating age-related macular degeneration and pharmaceutical purpose of medicine composition | |
| CN105343580A (en) | Traditional Chinese medicine composition for curing glaucoma and preparation method as well as use thereof | |
| CN105169242A (en) | Chinese and western medicine composition for treating diabetic complication of diabetic foot, preparing method of Chinese and western medicine composition and application of Chinese and western medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151014 |